Patients living with Alzheimer’s disease and their families may finally be getting a glimpse of hope in a Biogen Idec clinical trial, which shows a new drug may sharply slow the spread of the disease. The drug, which is called aducanumab, appeared to dramatically improve results when given at a high dose, though the early-stage clinical trial will have to be replicated for confirmation.
Read it at The New York Times
